Moderna Inc (NASDAQ:MRNA) finished Friday with an addition of $3.02 to close at $103.29, an upside of 3.01 percent. An average of 2,880,160 shares of common stock have been traded in the last five days. There was a gain of $3.30 in the past week, and it reached a new high 19 times over the past 12 months. The last 20 days have seen an average of 3,736,320 shares traded, while the 50-day average volume stands at 4,061,488.
MRNA stock has decreased by -11.43% in the last month. The company shares reached their 1-month lowest point of $97.11 on 09/25/23. With the stock rallying to its 52-week high on 01/18/23, shares of the company touched a low of $95.02 and a high of $217.25 in 52 weeks. It has reached a new high 6 times so far this year and lost -42.50% or -$76.33 in price. In spite of this, the price is down -52.46% from the 52-week high.
Insider Transactions
MRNA stock investors should be aware that Moderna Inc (MRNA) stock had its last reported insider trading activity 3 days ago on Sep 27. In this transaction, the insider spent $989,646. Director, AFEYAN NOUBAR, disposed of 15,000 shares at a price of $104.74 on Sep 20. The insider now owns more than $1,571,090 worth of shares. Prior to that, President Hoge Stephen went on to Sale 15,000 shares at $112.99 each on Sep 15. An amount of $1,694,850 was transacted.
Valuation Metrics
Moderna Inc (MRNA) has a trailing price-to-earnings (P/E) ratio of 37.95. The stock’s beta is 1.65. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.73, the price-to-book (PB) ratio at 2.32.
Financial Health
The quick ratio of Moderna Inc for the recent quarter was 3.16, and the current ratio was 3.39, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.06 and a total debt to equity ratio of 0.07 for the recent quarter. Its gross profit as reported stood at $13.85 billion compared to revenue of $19.26 billion.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$1.38 billion in the quarter, while revenues were grew 259.2%. Shareholders own equity worth $380.59 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Moderna Inc (MRNA) price momentum. RSI 9-day as of the close on 29 September was 48.45%, suggesting the stock is Neutral, with historical volatility in this time frame at 33.68%.
As of today, MRNA’s price is $99.86 +3.30% or $3.30 from its 5-day moving average. MRNA is currently trading -8.65% lower than its 20-day SMA and -21.60% lower than its 100-day SMA. However, the stock’s current price level is -17.22% below the SMA50 and -37.45% below the SMA200.
The stochastic %K and %D were 21.44% and 13.82%, respectively, and the average true range (ATR) was 4.03. With the 14-day stochastic at 34.07% and the average true range at 4.21, the RSI (14) stands at 46.07%. The stock has reached -0.09 on the 9-day MACD Oscillator while the 14-day reading was at -2.94.
Analyst Ratings
TD Cowen downgraded Moderna Inc (NASDAQ: MRNA) to a a Market perform rating in its most recent analyst report. Previously, the stock was rated as an Outperform. The consensus rating for Moderna Inc (MRNA) among analysts is Overweight. According to current brokerage recommendations, 2 brokerage firms advise that investors sell MRNA, while 9 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 2 analysts, while 11 others rate it as a “buy”.
What is MRNA’s price target for the next 12 months?
Analysts predict a range of price targets between $66.00 and $430.00, with a median target of $167.00. Taking a look at these predictions, the average price target given by analysts for Moderna Inc (MRNA) stock is $179.31.
